Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation

 April 10, 2026

Pharmaceutical Business Review

Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan Lee.

M&A / DealsMetabolic & GLP-1Read full story

Post navigation

Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers →
← Roche and C4 Therapeutics to advance degrader-antibody conjugates research

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com